These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 17580258

  • 1. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R, Emmanoulides C.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [Abstract] [Full Text] [Related]

  • 2. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
    Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C.
    N Engl J Med; 2004 Dec 16; 351(25):2590-8. PubMed ID: 15602019
    [Abstract] [Full Text] [Related]

  • 3. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S.
    J Support Oncol; 2007 May 16; 5(5):231-5. PubMed ID: 17564153
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
    Radtke ML, Kolesar JM.
    J Oncol Pharm Pract; 2005 Sep 16; 11(3):121-5. PubMed ID: 16390600
    [Abstract] [Full Text] [Related]

  • 6. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM, Lenz KL.
    Ann Pharmacother; 2007 Jan 16; 41(1):86-94. PubMed ID: 17190850
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
    Rzepecki P, Sarosiek T, Barzal J, Oborska S, Nurzynski P, Wasko A, Szczylik C.
    J BUON; 2007 Jan 16; 12(4):477-82. PubMed ID: 18067205
    [Abstract] [Full Text] [Related]

  • 9. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
    Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S, Bishop M.
    Bone Marrow Transplant; 1999 Sep 16; 24(5):555-60. PubMed ID: 10482942
    [Abstract] [Full Text] [Related]

  • 10. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B, Rzepecki P, Manko J, Czyz A, Markiewicz M, Federowicz I, Tomaszewska A, Piatkowska-Jakubas B, Wrzesien-Kus A, Bieniaszewska M, Duda D, Szydlo R, Halaburda K, Szczepinski A, Lange A, Hellman A, Robak T, Skotnicki A, Jedrzejczak WW, Walewski J, Holowiecki J, Komarnicki M, Dmoszynska A, Warzocha K, Marianska B.
    Bone Marrow Transplant; 2007 Nov 16; 40(10):983-8. PubMed ID: 17846600
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R.
    Clin Ther; 2008 May 16; 30(5):964-73. PubMed ID: 18555943
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
    Bennett CL, George SL, Vose JM, Nemunaitis JJ, Armitage JL, Armitage JO, Gorin NC, Gulati SC.
    Stem Cells; 1995 Jul 16; 13(4):414-20. PubMed ID: 7549900
    [Abstract] [Full Text] [Related]

  • 15. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM, Violago L, Cofnas P, Bishop J, Jin Z, Bhatia M, Kung AL, George D, Garvin J, Satwani P.
    Pediatr Transplant; 2014 Mar 16; 18(2):211-6. PubMed ID: 24823628
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A.
    Pharmacotherapy; 2007 Oct 16; 27(10):1353-60. PubMed ID: 17896890
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced charges and costs associated with outpatient autologous stem cell transplantation.
    Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD.
    Bone Marrow Transplant; 1998 May 16; 21(9):927-32. PubMed ID: 9613786
    [Abstract] [Full Text] [Related]

  • 20. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
    Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G, Rabitsch W, Urban C, Linkesch W, Neumeister P.
    Bone Marrow Transplant; 2008 Aug 16; 42(4):275-9. PubMed ID: 18500368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.